FEATURE
|
Leveling the NSF Playing Field
August 31, 2009 | Inside Higher Ed
The 2007 American COMPETES Act asked the National Science Board to weigh the pros and cons in reassessing the cost sharing policies of the National Science Foundation. The board issued a report Friday calling for an end to the practice of "voluntary" cost sharing, while continuing "mandatory" contributions in a small number of industry-focused federal programs.
Read More
|
Corporate Venture Capital – An Alternative Route To Finance?
August 26, 2009 | Life Science Leader
The buzz around the biopharma industry is that the traditional venture capital (VC) companies are withdrawing from funding new pharma and biotech start-ups in favor of supporting their existing portfolio companies. Coupling this with the lack of IPOs during 2008 and 2009, this leaves a large funding void at the early-stage part of the industry.
Read More
Venture Model Makeover & Diet Plan—Step One
August 24, 2009 | Xconomy
A lot of people have been asking lately if the venture model is broken. But it seems to me that it’s just decrepit. Like an aging, rotund former football star, the venture industry is scratching its head and realizing that its glory days are long past.
Read More
Why Waltham Doesn't Matter
August 24, 2009 | Boston Globe
We used to think of the placid plateaus of Mount Money in Waltham as the epicenter of our local venture capital industry. While they've funded many great local companies, I submit that they simply don't matter anymore, and that the new core of Boston venture capital has moved in closer to the city
Read More
Related:
How “Place” Matters in Innovation
|
Biotech Innovation Being Threatened
August 29, 2009 | San Jose Mercury News
As leaders in the biotech industry sat this week in a conference room on Sand Hill Road, ground zero for venture capitalists, the news for biotech startup companies wasn't music to their ears. One investor went as far as calling the current investing climate "Armageddon" for biotech startups.
Read More
Biotechs Go Back to the Future by Re-Innovating Old Drugs
August 26, 2009 | Xconony
Biotechnology start-ups have long been seen as fearless innovators. But the news flow from San Diego this summer suggests the industry may have become a bit more cautious. More and more companies, it seems, are focused on reviving or repurposing older drugs - and avoiding the risks of inventing a medicine entirely from scratch.
Read More
|
|